Skip to main content
main-content

07.11.2018 | Original Article | Ausgabe 1/2019

Virchows Archiv 1/2019

BRAF mutation testing in melanoma: results from a German observational multicenter study

Zeitschrift:
Virchows Archiv > Ausgabe 1/2019
Autoren:
Arndt Hartmann, Peter Schirmacher, William Sterlacci, Winfried Koch, David B. Liesenfeld, Birgit Schif, Claus Garbe
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00428-018-2480-4) contains supplementary material, which is available to authorized users.

Abstract

Quality control of BRAF mutation testing methods used in routine practice is crucial for optimal treatment selection. In this prospective study, we assessed the impact of patient/sample characteristics on BRAF mutation testing results in patients with melanoma, during clinical practice. Data were collected on routine testing practices and documented mutation status in patients with melanoma stages IIIB, IIIC, or IV across 28 diagnostic pathology centers in Germany. Patient/sample data collected included: patient age, location of primary melanoma and metastases, origin of sample, melanoma subtype, and quality of tissue. Statistical influence of patient/sample characteristics on BRAF mutation rate was assessed using multiple logistic regression analyses and statistical models developed to predict the probability of BRAF mutations for individual patient cohorts. Data/samples from 642 patients with melanoma were analyzed. BRAF mutations were documented in 241/642 patients (37.5%). The primary statistical model to predict BRAF mutation rates included: age (continuous), origin of sample, method of mutation analysis, and quality of tissue. Analyses of post hoc collected data identified major deviations between documented mutation rates included in this study vs. routinely recorded mutation rates for three centers. When samples from these centers were excluded, the influence of testing method was no longer statistically significant. The final model included patient age, origin of sample (including metastasis location), and quality of tissue. Once validated in an independent population, this type of model could allow pathology centers to compare the performance of their testing methods with what would be expected based on patient, tumor, and sample characteristics.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Nicht verpassen: e.Med bis 13. März 2019 100€ günstiger im ersten Jahr!

Zusatzmaterial
ESM 1 (DOCX 37 kb)
428_2018_2480_MOESM1_ESM.docx
ESM 2 (DOCX 35 kb)
428_2018_2480_MOESM2_ESM.docx
ESM 3 (DOCX 30 kb)
428_2018_2480_MOESM3_ESM.docx
High Resolution Image (EPS 2517 kb)
428_2018_2480_MOESM4_ESM.eps
High Resolution Image (EPS 2369 kb)
428_2018_2480_MOESM5_ESM.eps
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2019

Virchows Archiv 1/2019 Zur Ausgabe

Neu im Fachgebiet Pathologie

04.02.2019 | Schwerpunkt: Gynäkopathologie | Ausgabe 1/2019 Open Access

Fallstricke und Probleme bei der Differenzialdiagnose epithelialer Ovarialtumoren

01.02.2019 | Schwerpunkt: Gynäkopathologie | Ausgabe 1/2019

S3-Leitlinie Diagnostik und Therapie des Endometriumkarzinoms

Anforderungen an die Pathologie

01.02.2019 | Schwerpunkt: Gynäkopathologie | Ausgabe 1/2019 Open Access

Vorläuferläsionen der Endometriumkarzinome

01.02.2019 | Schwerpunkt: Gynäkopathologie | Ausgabe 1/2019

TNM-Klassifikation gynäkologischer Tumoren

Was bleibt über 2017 hinaus zu tun?